E
CPRX

Ergoteles’s Catalyst Pharmaceutical CPRX Stock Holding History

Ergoteles’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-44,934
Closed -$604K – 216
2023
Q2 		$604K Buy
+44,934
New +$647K 0.03% 596
2023
Q1 		– Sell
-46,356
Closed -$862K – 1342
2022
Q4 		$862K Buy
+46,356
New +$714K 0.03% 513
2021
Q3 		– Sell
-33,700
Closed -$194K – 1281
2021
Q2 		$194K Buy
+33,700
New +$174K ﹤0.01% 1291

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ergoteles's CPRX Position: Q3 2023 in Review

Ergoteles sold out of Catalyst Pharmaceutical (CPRX) in Q3 2023, closing a stake of 44,934 shares — an estimated $604K sold.

Ergoteles first reported a position in CPRX in Q2 2021 and held it in 3 quarters. The position peaked at $862K in Q4 2022. 255 funds tracked by Wall St. Rank hold CPRX as of Q3 2023.

  • Ergoteles reported no remaining Catalyst Pharmaceutical position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 44,934 Catalyst Pharmaceutical shares in Q3 2023, an estimated $604K.
  • Ergoteles first reported a position in Catalyst Pharmaceutical in Q2 2021 and held it in 3 quarters.
  • Ergoteles's Catalyst Pharmaceutical position peaked at $862K in Q4 2022.
  • 255 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.